Tag Archives: CLARIFY
October 2019 Br J Cardiol 2019;26(4)
News from ESC 2019
Richard Armstrong, Amar Puttana, BJC Staff
ESC President, Professor Barbara Casadei Heart failure highlights PARAGON-HF fails primary end point but benefits for some Heart failure was a key theme of this year’s congress, accounting for more than 1,000 presentations. In the first hotline session of the Congress, the keenly awaited results from PARAGON-HF (Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction) were presented.1 Up to 64 million people worldwide have heart failure, and that number is rising as the population ages. Evidence-based treatment has focused on about half of these patients who have heart failure with reduced ejection fraction (<
August 2012 Br J Cardiol 2012;19(Suppl 2):S2–S11 doi:10.5837/bjc.2012.s06
Chronic stable angina guidelines – is there an emerging international consensus?
Professor Jose Lopez-Sendon, Dr Henry Purcell, Professor Paolo Camici, Dr Caroline Daly, Professor Jamil Mayet, Dr John Parissis, Professor Francesco Pelliccia, Professor Christophe Piot, Professor Rainer Hambrecht
Introduction Stable angina is the most common manifestation of coronary heart disease. While considered relatively benign in terms of prognosis, the condition confers a higher risk of cardiovascular events than in the general population, with average annual mortality rates of 1–2%. Guidelines for the management of stable angina are relatively conservative in their approach, given their process of development. Moreover, stable angina management has not been as rigorously evaluated in large randomised trials as other coronary conditions. The role of newer treatment options in management algorithms also merits wider consideration. This expert
For healthcare professionals only
